A phase I dose-escalation study of ABT-888 (veliparib) in combination with carboplatin in HER2-negative metastatic breast cancer (MBC).
S. Viswanathan
Stock Ownership - Abbott Laboratories
R. Wesolowski
No relevant relationships to disclose
R. M. Layman
No relevant relationships to disclose
G. Alejandra
No relevant relationships to disclose
B. Miller
No relevant relationships to disclose
J. J. Chalmers
No relevant relationships to disclose
S. Bejastani
No relevant relationships to disclose
W. Zhao
No relevant relationships to disclose
G. Pierluigu
No relevant relationships to disclose
J. Cotrill
No relevant relationships to disclose
M. A. Phelps
No relevant relationships to disclose
L. J. Schaaf
No relevant relationships to disclose
S. M. Geyer
No relevant relationships to disclose
N. Hall
No relevant relationships to disclose
M. V. Knopp
No relevant relationships to disclose
C. L. Shapiro
No relevant relationships to disclose
M. A. Villalona-Calero
No relevant relationships to disclose
A. Chen
No relevant relationships to disclose
M. R. Grever
No relevant relationships to disclose
B. Ramaswamy
No relevant relationships to disclose